The use of magnetic resonance imaging in multiple sclerosis: Lessons learned from clinical trials

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 341-347

  Boneschi, Filippo Martinelli ^a   Rovaris, Marco ^a   Comi, Giancarlo ^a   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Clinical trials; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; PLACEBO;

BRAIN INJURY; BRAIN SIZE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOLOGY; PATIENT MONITORING; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; REPRODUCIBILITY OF RESULTS;

EID: 4344628691     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1067rr     Document Type: Review

References (71)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H. McAlpine's multiple sclerosis, third edition. London, UK: Churchill Livingstone, 1998.
3. Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001; 8: 27-35.
4. Sormani MP, Rovaris M, Bagnato F, Molyneux P, Bruzzi P, Pozzilli C et al. Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. Neurology 2001; 57: 1883-85.
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
6. Paty DW, Li DK, Oger JJ, Kastrukoff L, Koopmans R, Tanton E et al. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 1994; 36: S95-96.
7. Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 1988; 45: 746-48.
8. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990; 40: 971-75.
9. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-704.
10. Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C et al. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Mult Scler 2002; 8: 119-23.
11. Filippi M, Rovaris M, Rice GPA, Sormani MP, Iannucci G, Giacomotti L et al. The effect of cladribine on T1 'black hole' changes in progressive MS. J Neurol Sci 2000; 176: 42 -44.
12. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000; 123: 2256-63.
13. Barkhof F, van Waesberghe JH, Filippi M, Yousry T, Miller DH, Hahn D et al. T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001; 124: 1396-402.
14. Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA et al. The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57: 2185-90.
15. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology 2001; 57: 731-33.
16. Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Neurology 2000; 55: 185-92.
17. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6-16.
18. Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998; 121: 2011- 20.
19. Filippi M, Horsfield MA, Ader HJ, Barkhof F, Bruzzi P, Evans A et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998; 43: 499-506.
20. van Walderveen MA, Kamphorst W, Scheltens PH, van Waesberghe JHTM, Ravid R, Valk J et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-88.
21. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676-95.
22. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6: 373-77.
23. Kalkers NF, Bergers E, Castelijns JA, van Walderveen MA, Bot JC, Ader HJ et al. Optimizing the association between disability and biological markers in MS. Neurology 2001; 57: 1253-58.
24. Sormani MP, Bruzzi P, Comi G, Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002; 58: 417-21.
25. Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L et al. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology 2003; 60: 1462-66.
26. Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997; 244: 76-84.
27. Filippi M, Dousset V, McFarland HF, Miller DH, Grossman RI. The role of MRI in the diagnosis and monitoring of multiple sclerosis. Consensus report of the 'White Matter Study Group' of the International Society for Magnetic Resonance in Medicine. J Magn Reson Imag 2002; 15: 499-504.
28. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-97.
29. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
30. Scotti G, Gerevini S. Diagnosis and differential diagnosis of acute transverse myelopathy. The role of neuroradiological investigations and review of the literature. Neurol Sci 2001; 22: S69-73.
31. Rovaris M, Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol 1999; 12: 337-44.
32. Lucchinetti C, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001; 14: 259-69.
33. Li DKB, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. MRI results. Neurology 2001; 56: 1505-13.
34. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
35. Waubant E, Goodkin DE, Sloan R, Andersson PB. A pilot study of MRI activity before and during interferon beta-1a therapy. Neurology 1999; 53: 874-76.
36. Tortorella C, Viti B, Bozzali M, Sormani MP, Rizzo G, Gilardi MC et al. A magnetization transfer histogram study of normal appearing brain tissue in multiple sclerosis. Neurology 2000; 54: 186-93.
37. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56: 304-11.
38. Blinkenberg M, Rune K, Jensen CV, Ravnborg M, Kyllingsbaek S, Holm S et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 2000; 54: 558-64.
39. Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 2342-52.
40. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol 2002; 23: 985-88.
41. Rovaris M, Bozzali M, Iannucci G, Ghezzi A, Caputo D, Montanari E et al. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. Arch Neurol 2002; 59: 1406-12.
42. Dehmeshki J, Chard DT, Leary SM, Watt HC, Silver NC, Tofts PS et al. The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 2003; 250: 67-74.
43. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
44. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-95.
45. Reddy H, Narayanan S, Arnoutelis R, Jenkinson M, Antel J, Matthews PM et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 2000; 123: 2314-20.
46. Rocca MA, Falini A, Colombo B, Scotti G, Comi G, Filippi M. Adaptive functional changes in the cerebral cortex of patients with non-disabling MS correlate with the extent of brain structural damage. Ann Neurol 2002; 51: 330-39.
47. Owens T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 2003; 16: 259-65.
48. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433-37.
49. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998; 43: 79-87.
50. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-55.
51. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
52. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
53. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-47.
54. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714-18.
55. Filippi M, Grossman RI, Comi G. Magnetization transfer in multiple sclerosis. Neurology 1999; 53 (Suppl 3).
56. Filippi M, Inglese M. Overview of diffusion-weighted magnetic resonance studies in multiple sclerosis. J Neurol Sci 2001; 186: S37-S43.
57. Filippi M, Arnold DL, Comi G. Magnetic resonance spectrescopy in multiple sclerosis. Milan, Italy: Springer-Verlag, 2000.
58. van Waesberghe JHTM, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747-54.
59. Rovaris M, Bozzali M, Santuccio G, Ghezzi A, Caputo D, Montanari E et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001; 124: 2540-49.
60. Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 2003; 126: 2323-32.
61. van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996; 36: 632-36.
62. Rocca MA, Mastronardo G, Rodegher M, Comi G, Filippi M. Long term changes of MT-derived measures from patients with relapsing-remitting and secondary-progressive multiple sclerosis. AJNR Am J Neuroradiol 1999; 20: 821- 27.
63. Richert ND, Ostuni JL, Bash CN, Duyn JH, McFarland HF, Frank JA. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 1998; 19: 1705 -13.
64. Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001; 7: 49-58.
65. Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S. Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a. Neurology 2000; 54: 1741-45.
66. Inglese M, van Waesberghe JHTM, Rovaris M, Beckmann K, Barkhof F, Hahn D et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 2003; 60: 853-60.
67. Grossman RI, Lenkinski RE, Ramer KN, Gonzalez-Scarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992; 13: 1535 -43.
68. Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccioli GP et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 1998; 64: 204-12.
69. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001; 248: 979-86.
70. Parry A, Corkill R, Blamire AM, Palace J, Narayanan S, Arnold D et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003; 250: 171-78.
71. Khan O, Shen Y, Ching W, Caon C, Sonenvirth E, Latif Z et al. Combining immunomodulation and neuroprotection: cerebral axonal recovery in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate (abstract). Mult Scler 2003; 9: S63.